News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC
14 Jun 2024
byJairia Dela Cruz
Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.
14 Jun 2024

Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024
byStephen Padilla
Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.
14 Jun 2024






